| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6d79f70dd005120c0670419fe090ad9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b74b2d76f8432bacf2965cd37a86f98 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 |
| filingDate |
2006-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26419c4d5c54029053e497f398081e15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac957108bf1f43bcf2736b760d00b9dc |
| publicationDate |
2010-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-PI0616093-A2 |
| titleOfInvention |
use of metalloproteinases (typ) tissue inhibitor linked to glycosylphosphatidylinositol (gpi) fixations for skin lesion treatment |
| abstract |
The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI) fixed tissue inhibitors of metalloproteinases (TIMPs) and their use for cancer treatment and regenerative medicine. By this approach, GPI-fixed TIMP proteins are incorporated into the surface membrane of tumor cells and make tumor cells sensitive to FAS-induced apoptosis. In addition, the fusion constructs of the present invention are effective agents useful in curing applications. In one embodiment, TIMP is mucin bound followed by GPI to increase surface presentation. The use of GPI to bind TIMP makes the resulting fusion protein particularly useful as an anti-cancer agent for cancer treatment, and in particular any residual cancer following incomplete surgical resection of primary tumors in an individual. |
| priorityDate |
2005-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |